Immune thrombocytopenia (ITP) trials in United States

In United States 19 Also abroad 120

16 of 19 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Where
Albany, Ann Arbor, Boston, Clovis, Danvers, Greenville, Los Angeles, Minneapolis, New Orleans, Ogden, Peoria, Portland, Rochester, Seattle, The Bronx, Torrance, Washington D.C.
Age
18 years and over
People
60 worldwide
Run by
Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00
Phase 2Taking people
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Where
Billings, Chandler, Covington, Durham, East Brunswick, Fayetteville, Fort Worth, Hinsdale, Jacksonville, Kansas City, Margate, Miami, New Haven, Orlando, Philadelphia, Pittsburgh, Rochester, Salt Lake City, Sioux Falls, Stamford, Summit, The Bronx, Torrance
Age
18 years and over
People
164
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07421167
Phase 1/2Taking people
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Where
Austin, Houston, Los Angeles, Miami, New Orleans, Palo Alto, Peoria, Rochester, The Woodlands, Washington D.C.
Age
18 years to 64 years
People
68 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00
Phase 3Taking people
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Atlanta, Bethesda, Boston, Cleveland, Denver, Durham, Greenville, Hot Springs, Houston, Indianapolis, Iowa City, Kansas City, Los Angeles, Louisville, Milwaukee, New York, Norfolk, Philadelphia, Portland, San Diego, Seattle, The Bronx, Washington D.C., Worcester
Age
18 years and over
People
171 worldwide
Run by
Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00
Phase 3Taking people
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Where
Atlanta, Boston, Cleveland, Denver, Durham, Greenville, Hot Springs, Houston, Indianapolis, Iowa City, Kansas City, Los Angeles, Louisville, Milwaukee, Morristown, New York, Norfolk, Philadelphia, Portland, San Diego, Seattle, The Bronx, Washington D.C., Worcester
Age
18 years and over
People
150 worldwide
Run by
Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00
Phase 2Taking people
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Where
Boston, Cooper City, Fairfax, Glendale, Lone Tree, Los Angeles, New Haven, Seattle, The Bronx
Age
18 years and over
People
56 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07104565 · EU 2025-521286-27-00
Phase 3Taking people
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Where
Greenville, Los Angeles, Shirley
Age
18 years to 70 years
People
40 worldwide
Run by
Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00
Phase 1/2Taking people
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Where
Boston, Omaha, Rochester
Age
18 years and over
People
60 worldwide
Run by
CRISPR Therapeutics AG
See details and how to joinNCT07549698
Phase 3Taking people
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Where
Fredericksburg, Long Beach, Peoria
Age
18 years to 100 years
People
126
Run by
Amgen
See details and how to joinNCT07700238
Phase 2Taking people
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Where
Boston, Greenville, Washington D.C.
Age
18 years to 80 years
People
30 worldwide
Run by
Nuvig Therapeutics, Inc.
See details and how to joinNCT07095127 · EU 2024-520359-26-00
Phase 1Taking people
OM336 in Autoimmune Cytopenias
Where
Ann Arbor, Duarte, Seattle, Washington D.C.
Age
18 years to 75 years
People
32 worldwide
Run by
Lakefront Biotherapeutics West LLC
See details and how to joinNCT07083960
Phase 1/2Not yet taking people in United States
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Where
Webster
Age
18 years to 80 years
People
72
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT07738822
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Amarillo, Austin, Baltimore, Chapel Hill, Columbus, Houston, Lake Success, New York, Orange, Philadelphia, Portland
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 2Not yet taking people in United States
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Where
Boston, Houston, Seattle
Age
18 years and over
People
52 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07603557
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Where
Aurora, Chicago, Cleveland, Columbus, Detroit, Durham, Greenville, Iowa City, Little Silver, Los Angeles, Minneapolis, New Haven, New Orleans, Oceanside, Oklahoma City, Phoenix, Washington D.C., Westbury
Age
18 years and over
People
69 worldwide
Run by
argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00
Phase 1Taking people
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Where
Vahalla
Age
1 year to 21 years
People
20
Run by
New York Medical College
See details and how to joinNCT04323748